Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes (DIABIL-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02411253
Recruitment Status : Active, not recruiting
First Posted : April 8, 2015
Last Update Posted : February 2, 2021
Iltoo Pharma
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2022